DSM-Firmenich

Nutrition's good 'health'

18/11/20 -"We have factored in our more positive stance regarding DSM's future strategy in Nutrition, which goes much closer to the individual needs to stay healthy. This will lead to a higher profitability as ..."

PDF page sample
Pages
67
Language
English
Published on
18/11/20
Download
You may also be interested by these reports :
17/08/26
Symrise (ADD; Germany) is the smallest of the four Flavours & Fragrances majors and the one that bought its way to diversification. The shares are up ...
13/08/26
Umicore (Reduce, Belgium) has been a money maker for investors, albeit at a cost to their blood pressure levels. Since we last teased the company ...
12/08/26
Brenntag delivered a strong Q2, with operating EBITDA of €463m, supported by favourable chemical pricing, improved commercial execution and €41m of ...
12/08/26
K+S reported a strong set of numbers for Q2 2026, largely driven by volumes. EBITDA gained significantly from the higher volumes and prices, although ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO